Humira Biosimilar Trends and Forecast
The future of the global humira biosimilar market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets. The global humira biosimilar market is expected to grow with a CAGR of 26.0% from 2024 to 2030. The major drivers for this market are growing prevalence of autoimmune diseases, rising pharmaceutical firms to develop and commercialize biosimilar versions of humira, and biosimilars provide a more affordable alternative to the reference biologic medicine.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Humira Biosimilar by Segment
The study includes a forecast for the global humira biosimilar by product type, patient age, indication, distribution channel, and region.
Humira Biosimilar Market by Product Type [Shipment Analysis by Value from 2018 to 2030]:
• Biosimilar Humira (Adalimumab)
• Interchangeable Biosimilar Humira
Humira Biosimilar Market by Patient Age [Shipment Analysis by Value from 2018 to 2030]:
• Adult Patients
• Pediatric Patients
• Geriatric Patients
Humira Biosimilar Market by Indication [Shipment Analysis by Value from 2018 to 2030]:
• Rheumatoid Arthritis
• Psoriasis
• CrohnÄX%$%XS Disease
• Ulcerative Colitis
• Ankylosing Spondylitis
• Juvenile Idiopathic Arthritis
• Others
Humira Biosimilar Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others
Humira Biosimilar Market by Region [Shipment Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
List of Humira Biosimilar Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies humira biosimilar companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the humira biosimilar companies profiled in this report include-
• Amgen
• Samsung Bioepis
• Sandoz International
• Mylan
• Boehringer Ingelheim International
• Pfizer
• Fresenius Kabi
• Coherus BioSciences
• Biogen
• AbbVie
Humira Biosimilar Market Insights
Lucintel forecasts that biosimilar humira (adalimumab) will remain the larger segment over the forecast period.
Within this market, hospital pharmacy will remain the largest segment.
North America will remain the largest region over the forecast period due to the expiration of humiraÄX%$%Xs patents, the market for biosimilars is projected to expand in the region.
Features of the Global Humira Biosimilar Market
Market Size Estimates: Humira biosimilar market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Humira biosimilar market size by product type, patient age, indication, distribution channel, and region in terms of value ($B).
Regional Analysis: Humira biosimilar market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different product type, patient age, indication, distribution channel, and regions for the humira biosimilar market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the humira biosimilar market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the growth forecast for humira biosimilar market?
Answer: The global humira biosimilar market is expected to grow with a CAGR of 26.0% from 2024 to 2030.
Q2. What are the major drivers influencing the growth of the humira biosimilar market?
Answer: The major drivers for this market are growing prevalence of autoimmune diseases, rising pharmaceutical firms to develop and commercialize biosimilar versions of humira, and biosimilars provide a more affordable alternative to the reference biologic medicine.
Q3. What are the major segments for humira biosimilar market?
Answer: The future of the global humira biosimilar market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets.
Q4. Who are the key humira biosimilar market companies?
Answer: Some of the key humira biosimilar companies are as follows:
• Amgen
• Samsung Bioepis
• Sandoz International
• Mylan
• Boehringer Ingelheim International
• Pfizer
• Fresenius Kabi
• Coherus BioSciences
• Biogen
• AbbVie
Q5. Which humira biosimilar market segment will be the largest in future?
Answer: Lucintel forecasts that biosimilar humira (adalimumab) will remain the larger segment over the forecast period.
Q6. In humira biosimilar market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to the expiration of humiraÄX%$%Xs patents, the market for biosimilars is projected to expand in the region.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the humira biosimilar market by product type (biosimilar humira (adalimumab) and interchangeable biosimilar humira), patient age (adult patients, pediatric patients, and geriatric patients), indication (rheumatoid arthritis, psoriasis, crohnÄX%$%Xs disease, ulcerative colitis, ankylosing spondylitis, juvenile idiopathic arthritis, and others), distribution channel (hospital pharmacies, retail pharmacies, online pharmacies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Humira Biosimilar Market, Humira Biosimilar Market Size, Humira Biosimilar Market Growth, Humira Biosimilar Market Analysis, Humira Biosimilar Market Report, Humira Biosimilar Market Share, Humira Biosimilar Market Trends, Humira Biosimilar Market Forecast, Humira Biosimilar Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.